The human prostatic carcinoma cell line LNCaP is sensitive to TNF-a treatment and expresses wild-type p53. To analyse the possible role of p53 in TNF-amediated apoptosis, we generated a derivative of LNCaP, LN-56, expressing a dominant-negative element of p53, GSE56. P53 inactivation in LN-56 was associated with an increased resistance to apoptosis induced by TNF-a. Surface expression of TNF-a receptors was unchanged in LN-56 compared to LNCaP. TNF-a treatment resulted in accumulation of p53 in LNCaP and upregulation of p21/WAF1. Activation of caspase-7 and PARP proteolysis were delayed in LN-56 under TNF-a treatment. TNF-a-induced apoptosis in LNCaP cells was accompanied by caspase-dependent proteolysis of p21/WAF1 and Rb, which was signi®-cantly attenuated in LN-56. Cytochrome c release was induced by TNF-a treatment in both cell lines, but caspase-9 was not activated. LNCaP and LN-56 were injected s.c. in nude mice and tumors were identi®ed in all LN-56, but not LNCaP, bearing mice indicating that p53 plays an important role in growth control of prostatic neoplasms. Interestingly, accumulation of p53 in TNF-a-treated LNCaP cells was decreased in the presence of the caspase inhibitor Z-VAD-FMK, suggesting a new role of activated caspases in acceleration of p53 response. In summary, these results indicate that p53 is involved in TNF-a-mediated apoptosis in LNCaP.
Introduction
p53 is a regulator of genotoxic stress that plays an important role in DNA damage response and repair, cell cycle regulation and in triggering apoptosis after cell injury. Moreover, p53 is the most commonly mutated gene in human malignancy which makes p53 a major potential target for gene-speci®c cancer therapy (reviewed in Bellamy et al., 1997) . Unlike in other types of cancer, p53 abnormalities in prostate cancer are relatively rare, ranging, according to dierent estimates, between 4 and 42%, with a mean of about 15%. In one study, comprehensive analysis of 67 prostate cancers suggested that p53 inactivation is rare in primary tumors and not essential to the development of metastases (Brooks et al., 1996) . However, analysis of the topographical distribution of the p53 mutant genotype revealed intratumoral heterogeneity among multifocal tumors within a prostate (Mirchandani et al., 1995) and the authors further suggested that these ®ndings may explain the wide discrepancy in the reported detection of p53 abnormalities in prostate specimens. A fundamental role of p53 in prostate cancer progression was found in the mouse prostate reconstitution (MPR) model (Thompson et al., 1995) . Prostate cancer was identi®ed in 100% of heterozygous and homozygous p53 mutant MPRs with metastatic deposits in 95% of the mice, but no metastasis was found in the case of wild-type p53. In addition, the authors noted that the pattern of metastasis was remarkably similar to that in human prostate cancer. It is noteworthy that in many cases lack of p53 mutations does not mean that p53 is functionally active in tumors. For example, in neuroblastomas p53 is sequestered in the cytosol (Moll et al., 1996) , in sarcomas and cervical carcinomas it is inactivated by Mdm2 and E6 proteins, respectively (Miller et al., 1996; Rapp and Chen, 1998) , and in melanomas wildtype of p53 activity is suppressed by an as yet unknown mechanism (Bae et al., 1996) . It remains unclear whether p53 in prostate cancer is functionally active and how it eects the biology of these tumors.
Among several permanent human prostatic carcinoma cell lines described in the literature, LNCaP is the most adequate in vitro model of human prostate cancer (reviewed in van Steenbrugge et al., 1989) . The growth of LNCaP is androgen-dependent, LNCaP secretes prostate speci®c antigen (PSA), expresses prostatic acid phosphatase and expresses functionally active androgen receptor, albeit a mutated one. It has been also shown that LNCaP expresses wild-type p53 (Isaacs et al., 1991; Carroll et al., 1993) . It therefore could serve as a valuable model of human prostate cancer, allowing one to address the role of p53 in prostate cancer biology, including its sensitivity to anti-cancer therapy both by chemotherapeutic drugs and physiological regulators of cell proliferation and survival. It has been reported that LNCaP is highly sensitive to the cytotoxic eect of TNF-a (Nakajima et al., 1996; Sensibar et al., 1995; Zhao et al., 1992) . TNF-a is a cytokine capable of initiating a broad range of biological eects including apoptosis of some tumor cells (reviewed in Wong et al., 1997) . These eects are mediated through TNF receptor oligomerization which activates a caspase cascade via cytoplasmic adaptor proteins and TNFreceptor complexes. These complexes also interact with RIP and TRAF2 proteins which are involved in the activation of c-Jun aminoterminal kinases and NF-kB Liu et al., 1996; Song et al., 1997) . TNF-a has been shown to induce apoptosis and accumulation of p53 in various cell types, suggesting the potential involvement of p53 in TNF-a-induced cell death. p53 accumulation was observed in the ME-180 cell line (Donato and Perez, 1998) , rat glioma cells (Yin et al., 1995) , ovarian cancer cells (Gotlieb et al., 1994) , and in human breast carcinoma MCF-7 cells (Jeoung et al., 1995) after TNF-a treatment. Cai et al. (1997) investigated the relationship between p53 function and resistance to TNF-a treatment using TNF-a-resistant sublines obtained from the TNF-a-sensitive MCF-7 cell line. One subline was selected by continuous exposure to TNF-a, while a second subline was identi®ed to be TNF-a-resistant after the development of resistance to doxorubicin. Analysis of p53 in these sublines showed that both sublines exhibited mutant p53 which was associated with loss of p53 transactivation activities. Whether additional genomic alterations occurred during selection procedure of these sublines remained unclear.
In this study, we switched o p53 function in LNCaP cells by introduction of a potent p53 inhibitor, genetic suppressor element 56 (GSE-56), which resulted in generation of LNCaP subline, LN-56. It has previously been shown (Ossovskaya et al., 1996) that expression of GSE-56, which corresponds to the Cterminal portion of p53 (a.a. 275 ± 368), results in the accumulation of p53 in inactive conformation and inhibition of p53 transactivation. Thus, LNCaP diers from LN-56 by only a single genetic alteration speci®cally targeting the function of p53, and allowed us to investigate the role of p53 in TNF-a-induced apoptosis with a unique model system.
Results

Variant of LNCaP overexpressing GSE-56 (LN-56)
To investigate the role of p53 in TNF-a-induced apoptosis, we transfected LNCaP with a plasmid containing GSE-56, and as a control with the empty vector. Cells resistant to G418 were selected as a bulk culture and cells expressing GSE-56 were labeled as LN-56. It has been previously shown (Ossovskaya et al., 1996) that expression of GSE-56, which corresponds to the C-terminal portion of p53 (a.a. 275 ± 368), results in accumulation of p53 and inhibition of p53 transactivation. Expression of the truncated form of p53 encoded by GSE-56 in LN-56 was con®rmed by Western immunoblotting (Figure 1c ). p53 function was tested in the cells expressing GSE-56 by treating LNCaP and LN-56 with the DNA-damaging drug doxorubicin (DOX), a powerful inducer of p53 and p53-responsive genes, in particular p21/WAF1 (El Deiry et al., 1993) . In LNCaP, treatment with DOX resulted in the elevation of p53 and p21/WAF1 (Figure 1a ). In contrast, the amount of p53 in LN-56 was signi®cantly higher under normal growth conditions and is an indication of its inactive conformation caused by GSE-56. Neither p53 nor p21/WAF1 levels changed in LN-56 cells after treatment with DOX (Figure 1a,b) . Thus, expression of GSE-56 in LNCaP cells resulted in the expected inactivation of p53 function that allowed us to use LN-56 as a model to study p53-dependent eects in LNCaP cells by using a`clean' isogenic system. We have periodically checked out the status of p53 and p21, and sensitivity to TNF-a treatment during culturing of both cell lines (LNCaP from 24 to 86 passages and LN-56 from 3 to 54 passages) and have not found any dierences over the time.
TNF-a-induced apoptosis is suppressed in LN-56 cells
We compared sensitivity of LNCaP and LN-56 to treatment with TNF-a. As shown in Figure 2a , LN-56 was found to be signi®cantly more resistant to TNF-a than LNCaP: at least a 50% decrease in apoptotic cells was noted at any given dose of the cytokine. This Figure 1 Expression of p53 and p21/WAF1 in LNCaP and LN-56. Expression of p53 (a) and p21/WAF1 (b) was investigated by Western blot analysis. LNCaP and LN-56 were treated with doxorubicin (DOX) (1 mg/ml) for various times. Expression of p53 with mAb to N-terminal (1) and C-terminal epitopes (2) (c) was investigated in untreated cells. Cells were harvested and lysed in Laemmli sample buer, 20 mg proteins were separated on 4 ± 20% gradient SDS ± PAGE, blotted to nitrocellulose membrane, blocked with 5% nonfat dry milk in PBS containing 0.1% Tween-20 and then incubated with mouse mAbs. The blots were counterstained with goat antimouse lgG conjugated with HRP. The immunoreactive bands were visualized by incubation of the membrane with enhanced chemiluminescence reagent p53 dependent apoptosis in prostate cancer OW Rokhlin et al observation suggested that TNF-a induces apoptosis and acts through p53 in LNCaP cells. It has been shown that p53 may enhance the expression of the Fas receptor (CD95) in a variety of human normal and cancer cells (Owen-Schaub et al., 1995; Bennett et al., 1998; Fukazawa et al., 1999) . Bennett et al. (1998) found that surface expression of Fas and TNFRI in human vascular smooth muscle cells increased after induction of p53 by allowing cytoplasmic death receptors to accumulate at the cell surface. To test this possibility, we compared the expression of Fas and receptors to TNF-a in LNCaP and LN-56 cells. Although the levels of Fas were lower in LN-56 than in LNCaP, they did not dier in surface expression of either TNF-a receptors, TNFRI and TNFRII (Figure 3 ). Thus the relative resistance of LN-56 to TNF-a-induced apoptosis does not appear to be mediated by decreased levels of TNF-a receptors. It is noteworthy that p53-dependent modulation of the levels of surface Fas expression in LNCaP does not correlate with their sensitivity to Fas-mediated apoptosis; these cells were previously shown to be H-thymidine as described in Materials and methods and plated at a density of 7000 cells/well; TNF-a was added at the time of plating, and cells were harvested 48 h later. Caspase activity (b) was estimated with Ac-DEVD-AMC as a substrate that is cleaved by several dierent caspases. Cells were treated with TNF-a (20 ng/ ml) for various times. Cells were then harvested and lysates prepared and assayed as descibed in Material and methods. Measurements were calibrated against a standard curve of 7-amino-4-methylcoumarin (AMC) and data were expressed in nM of released AMC per mg of lysate proteins. Each point represents the mean value of three separate experiments, which gave similar results. (c) Inhibition of apoptosis by pan-caspase inhibitor Z-VAD-FMK. Inhibitor at the indicated concentrations, and TNF-a (20 ng/ml) were added at the time of cell plating, cultured for 48 h, and apoptosis was measured by DNA fragmentation assay. Each point represents mean values of three replicates in one of three separate experiments, which gave similar results Figure 3 Surface expression of Fas and TNFR in LNCaP and LN-56. Surface expression of Fas receptor and receptors I and II to TNF-a was estimated by¯ow cytometric analysis. Cells were incubated with mAb IPO-4, which reacts with the Fas-receptor (Rokhlin et al., 1997a) , and with mAbs to TNFRI and TNFRII (R & D Systems), and bound antibodies were detected with PElabeled goat Abs to mouse lg. Thick line, control with irrelevant mouse lg; thin line, speci®c expression completely resistant to Fas-induced cell death (Rokhlin et al., 1997a) .
Inactivation of p53 promotes tumor growth of LNCaP in nude mice
To investigate the role of p53 in long term survival, LNCaP and LN-56 were grown as subcutaneous xenografts in nude male BALB/c mice. 500 000 cells were injected along with Matrigel (®ve mice in each group) and after 5 weeks no growth was apparent in LNCaP bearing mice. In contrast, tumors were identi®ed in all LN-56 bearing mice and these tumors had a mean weight of 0.78 g. These results strongly suggest that p53 plays a fundamental role in long term survival and tumorogenicity of LNCaP.
Caspase activity during TNF-a-induced apoptosis in LNCaP and LN-56 cells
In order to investigate biochemical characteristics of apoptosis in LNCaP and LN-56, cells were treated with 20 ng/ml of TNF-a for various times, cytosolic extracts were prepared from control and treated cells, and ICE-(caspase-1 subfamily) and CPP32-like (caspase-3 subfamily) activity were determined in lysates using thē uorescent substrates, Ac-YVAD-AMC or Ac-DEVD-AMC, respectively. DEVD is also known as a substrate that is cleaved by several dierent caspases, not just caspase-3. We did not ®nd ICE-like activity in LNCaP under treatment with TNF-a (data not shown). However, we did detect a time-dependent DEVDase activity during TNF-a-mediated apoptosis (Figure 2b ), and this activity was induced at the same levels both in LNCaP and LN-56. We subsequently investigated the eects of dierent protease inhibitors in order to determine whether caspase activation is central in TNF-a-induced apoptosis. As shown in Figure 2c , Z-VAD-FMK, a caspase inhibitor with broad speci®city, inhibited TNF-a-mediated apoptosis. However, we did not ®nd any speci®c caspase or other protease inhibitor which was capable of preventing TNF-a-mediated apoptosis in LNCaP (Table 1) . We also examined the proteolysis of the nuclear enzyme PARP into its 85 kDa COOH-terminal fragment ( Figure 4 ) which has been widely used as a biochemical hallmark for the executioner phase of apoptosis (Lazebnik et al., 1994) . We noted that proteolysis of PARP was delayed in LN-56 compared to LNCaP after treatment with TNF-a, and the p85 band of PARP was more intense in LNCaP compared to LN-56. Thus, PARP proteolysis was found to be clearly p53-dependent. At the same time, PARP proteolysis was completely inhibited in the presence of the caspase inhibitor Z-VAD-FMK (data not shown).
The results obtained indicate the involvement of caspases in p53-dependent apoptosis in LNCaP and therefore we performed a series of experiments to determine which of the caspases play a role in TNF-ainduced apoptosis in LNCaP. We examined the role of selected caspases by using mAbs to caspase-2, -3, -7 and -8. We have previously shown that mAbs to caspase-3, -7 and -8 reacted with both proenzyme and the large subunit of activated caspases (Rokhlin et al., 1998) ; mAb to caspase-2 reacted with the small subunit, as described by the manufacturer (R & D Systems). As shown in Figure 5a , TNF-a does not activate caspase-8 in LNCaP; PC3 was used as a positive control for caspase-8 activation in these experiments (Rokhlin et al., 1998) . We also found that caspase-3 remained in its inactive form during treatment of LNCaP with TNF-a (Figure 5b ).
TNF-a was found to activate caspase-2 and -7 (Figure 5b,c) both in LNCaP and LN-56. We did not ®nd the dierences between LNCaP and LN-56 in caspase-2 activation (data not shown). However, the timing of caspase-7 activation was found to be p53-dependent. Caspase-7 was activated in LNCaP after 8 h of treatment with TNF-a and the levels of activated caspase-7 increased after 16 and 32 h of treatment ( Figure 5 ). The activated form of caspase-7 was identi®ed in LN-56 only after 16 h of treatment and the levels were signi®cantly lower compared to LNCaP.
To further investigate caspase activity in LNCaP and LN-56, we used a cell-free system of apoptosis . Cytochrome c and dATP were added to cytoplasmic extracts and caspase activity was invested by using¯uorogenic substrates. As shown in Figure 6 , cytochrome c/dATP was able to trigger caspase-3 subfamily activation in cytoplasmic extracts from both LNCaP and LN-56, and this activity was eectively blocked by the caspase-3 subfamily inhibitor Z-DEVD-FMK. Caspase activation in this system was found to be ten times higher compared to caspase activation in intact cells under TNF-a treatment (see Figure 2b and 6). These data indicate that caspases preexist in proenzyme form in the cytosol of LNCaP and LN-56, and that low levels of caspase activation are speci®cally dependent on TNF-a-mediated pathways. By Western blot analysis we examined the timedependent expression of p53 after treatment of LNCaP with TNF-a. As shown in Figure 7a , p53 expression increased after 4 h of treatment with TNFa and elevated levels of p53 remained up to 30 h. In order to determine the potential involvement of caspases in p53 accumulation, we examined the eect of Z-VAD-FMK on the induction of p53 after incubation of LNCaP with TNF-a. Surprisingly, Z-VAD-FMK inhibited elevation of p53 levels after TNF-a treatment (Figure 7a ). These data suggest that p53 accumulation in LNCaP after treatment with TNF-a depends, at least in part, on caspase activation. Since the induction of apoptosis and caspase activation is p53 dependent (see Figures 2a  and 5c ), it is reasonable to conclude that p53-caspase(s) interaction results in a positive regulatory loop that ampli®es apoptotic response in LNCaP. Apoptosis in LNCaP was associated with proteolytic cleavage of p21/WAF1 and Rb, which are known to be involved in cell growth regulations and apoptosis. Figure 7b shows that treatment of LNCaP with TNF-a resulted in elevated levels of p21/WAF1 which was also accompanied by p21/WAF1 proteolysis. This proteolysis was eectively inhibited in the presence of Z-VAD-FMK and therefore is mediated by one or more of the caspases. Neither accumulation of p21/WAF1 nor its cleavage was observed in LN-56. These data indicate that caspase-mediated proteolysis of p21/ WAF1 during TNF-a-mediated apoptosis is p53-dependent.
We have previously observed Rb proteolysis during Fas-mediated apoptosis in Fas-sensitive cell lines, PC3 and ALVA31 (Rokhlin et al., 1998) . We have also found that Rb cleavage was inhibited in PC3 by YVAD-CMK and DEVD-FMK, but Rb proteolysis in AVLA31 was prevented only by DEVD-FMK. In this study, we observed Rb proteolysis in LNCaP and LN-56 after TNF-a treatment (Figure 7c ). Rb proteolysis was prevented by Z-VAD-FMK (data not shown) and therefore is likely to be mediated by caspase(s) cleavage. Western blot analysis did not reveal signi®cant dierences between LNCaP and LN-56 in steady state levels of Rb. However, the levels of Rb proteolysis were found to be signi®cantly higher in LNCaP compared to LN-56. These data suggest that Rb proteolysis may also be p53-dependent. Figure 6 Cytochrome c/dATP induces DEVDase activity in cytoplamic extracts. Cytoplasmic extracts were prepared from untreated cells and incubated for 45 min with cytochrome c (5 mM) and dATP (1 mM) at 378C. Caspase activity was estimated with caspase-3-like¯uorogenic substrate, Ac-DEVD-AMC in the absence (zero point) or in the presence of caspase inhibitor Z-DEVD-FMK Figure 5 Caspase-2 and -7 are activated during TNF-a-mediated apoptosis. LNCaP and LN-56 were treated with TNF-a (20 ng/ ml) for various times; the Fas-sensitive cell line PC3 was treated with anti-Fas mAb (1 mg/ml) for 4 and 8 h. Expression of caspase-8 (a), -2 and -3 (b), and -7 (c) was investigated by Western blot analysis. Cells were harvested and lysed in 1% Triton X-100 lysis buer. Twenty mg of proteins were separated on 4 ± 20% gradient SDS ± PAGE, blotted to nitrocellulose membrane, blocked with 5% nonfat dry milk in PBS containing 0.1% Tween-20 and then incubated with mouse mAbs (a and b) or rabbit Abs (c). The blots were counterstained with goat antimouse or antirabbit IgG conjugated with HRP. The immunoreactive bands were visualized by incubation of the membrane with enhanced chemiluminescence reagent. As a positive control for the mAb to caspase-8 (a), activation of caspase-8 in the Fassensitive cell line PC3 was used (Rokhlin et al., 1998) 
Mitochondria do not play an essential role in TNF-amediated apoptosis in LNCaP
To examine the involvement of the mitrochondrial pathway in TNF-a-mediated apoptosis, we measured (1) cytochrome c release; (2) caspase-9 activation; and (3) production of peroxide radicals and the disruption of the mitochondrial transmembrane potential (DC m ) after TNF-a treatment. To measure cytochrome c release, LNCaP and LN-56 were treated with TNF-a for various times, cytosolic extracts were prepared under conditions that keep mitochondria intact (Yang et al., 1997) , and cytosolic cytochrome c levels were estimated by immunoblot analysis. We found that levels of cytochrome c slightly increased in both cell lines at 2 h of treatment and further increased up to 24 h (Figure 8a ). We also tested whether the release of cytochrome c was caspase-dependent. We observed that preincubation of LNCaP with Z-VAD-FMK (100 mM) had no eect on release of cytochrome c. Thus, cytochrome c release occurs upstream of caspase activation and appears to be p53-independent. We have also found that caspase-9 is not involved in a TNF-amediated apoptosis, since we observed neither proenzyme levels decrease nor the appearance of the activated subunit of caspase-9 after TNF-a treatment (Figure 8b ).
We further measured peroxide radical production using 2'-7'-dichloro¯uorescein diacetate (DCF-DA) and disruption of DC m using 3,3'-dihexyloxacarbocyanine iodide (DiOC 6 (3)). Nonylacridine orange (NAO) was used to measure mitochrondrial mass independently from DC m status of mitochondria. We found that TNF-a treatment slightly induced peroxide radical production in both cell lines. However, we did not observe disruption of DC m or a decrease of mitochondrial mass under TNF-a treatment (data not shown). Taken together, these data indicate that the mitochondrial pathway does not play an important role in p53-dependent TNF-a-mediated apoptosis.
Discussion
To gain insight into the possible interrelation between TNF-a-induced apoptosis and p53 pathway in LNCaP, we investigated the eect of functional inactivation of p53 on cellular responses to TNF-a treatment. We switched o p53 function by transfection of LNCaP with genetic suppressor element 56 (GSE-56, Ossovskaya et al., 1996) which resulted in generation of the LN-56 subline. This subline diers from LNCaP by only a single genetic alteration, speci®cally targeting the function of p53. The established system allowed us to demonstrate the involvement of p53 in TNF-ainduced apoptosis and to investigate the mechanisms of p53-dependent apoptosis.
Introduction of GSE-56 into LNCaP cells changed their sensitivity to TNF-a. It has been recently shown that p53-induced apoptosis can occur by p53-mediated increasing of surface Fas and TNFRI expression (7) of the pan-caspase inhibitor Z-VAD-FMK (100 mM). (b) p21/ WAF1 expression. LNCaP and LN-56 were treated with TNF-a (20 ng/ml) for various times. LNCaP was also treated for 16 h with TNF-a in the presence (+) or absence (7) of Z-VAD-FMK (100 mM). (c) Rb expression. LNCaP and LN-56 were treated with TNF-a (20 ng/ml) for various times. In all experiments, cells were harvested, lysed in sample buer and expression of proteins was analysed by Western blot, as described in the legend to Figure 1 p53 dependent apoptosis in prostate cancer OW Rokhlin et al (Bennett et al., 1998) . Considering these data, we compared cell surface expression of Fas, TNFRI and TNFRII both in LNCaP and LN-56. We found that the levels of Fas were lower in LN-56 than in LNCaP. However, p53-dependent modulation of the levels of surface Fas expression in LNCaP does not correlate with their sensitivity to Fas-mediated apoptosis. These cells were previously shown to be resistant to Fasinduced cell death although the Fas expression in LNCaP was on the same levels as in the Fas-sensitive cell lines, PC3 and ALVA31 (Rokhlin et al., 1997a) . We did not ®nd any dierences between LNCaP and LN-56 in the surface expression of both TNF-a receptors, TNFRI and TNFRII (Figure 3) . Thus, the relative resistance of LN-56 to TNF-a-induced apoptosis was not mediated by the modulation of levels of TNF-a receptors. It has recently been shown that cytochrome c is released from the mitochondrial intermembrane space into the cytosol following the induction of apoptosis by many dierent stimuli (Susin et al., 1998) . Marcelli et al. (1999) found that treatment of LNCaP with sodium phenylacetate and staurosporin induced caspase-independent release of cytochrome c from the mitochondria to the cytosol. In this study, we have shown that cytochrome c release occurred after TNF-a-treatment in both LNCaP and LN-56 and that this process is caspase-independent, as described by Marcelli et al. (1999) . These data suggest that cytochrome c release in LNCaP occurs upstream of activation of the caspase cascade under dierent apoptogenic stimuli. However, it does not appear that mitochondrial pathway play an essential role in TNF-a-induced apoptosis in LNCaP, since cytochrome c release does not result in caspase-9 activation.
We observed p53-dependent elevation of p21/WAF1 levels, which was accompanied by p21/WAF1 proteolysis during TNF-a-mediated apoptosis in LNCaP, but not in LN-56. p21/WAF1 proteolysis was inhibited in LNCaP in the presence of the pan-caspase inibitor Z-VAD-FMK. The link between p21/WAF1 proteolysis and apoptosis induced by g-irradiation was observed in ML-1 cells (human myeloblastic leukemia), (Gervais et al., 1998) . The authors observed the p14 proteolytic fragment of p21/WAF1 and showed that proteolysis of p21/WAF1 abolished its interaction with proliferation cell nuclear antigen (PCNA). They suggested that the cleavage of p21/WAF1 might interfere with DNA repair, causing prolonged presence of DNA lesions that may trigger apoptosis. Interestingly, p21/WAF1 accumulation and proteolysis has been also found in response to TNF-a treatment in ME-180 cells, and analysis of a TNF-a-resistant subline indicated that this process might be p53-dependent (Donato and Perez, 1998) .
p53 dependence of proteolytic cleavage in LNCaP was shown for another important growth controlling protein, Rb. We have previously reported caspasemediated interior cleavage of Rb in Fas-sensitive prostatic carcinoma cell lines, PC3 and ALVA31 (Rokhlin et al., 1998) . Here, we observed Rb proteolysis in LNCaP after TNF-a treatment, and, in addition, the levels of Rb proteolysis were found to be p53-dependent. Interior cleavage of Rb has been previously reported in Jurkat during DNA-damageinduced apoptosis (Fattman et al., 1997) . Gottlieb and Oren (1998) found cleavage of Rb in the IL-3-dependent lymphoid cell line DA-1 during apoptosis induced by IL-3 withdrawal. They have shown that depletion of IL-3 resulted in caspase-mediated Rb cleavage and occurred preferentially in the cells which expressed functional p53. Importantly, their data suggest that p53 itself appears to play a role in Rb cleavage, possibly by controlling caspase activation. Our data suggest that Rb proteolysis may play an important role at the late stages of apoptosis but does not play a crucial role during the early events of apoptosis in LNCaP. Rb cleavage was observed only after 16 h of treatment with TNF-a; p21/WAF1 proteolysis was noted earlier. Thus, p53 appears to control both the early and late events of apoptosis in LNCaP, apparently interacting with p21/WAF1 and Rb, respectively.
Our observations on the proteolysis of p21/WAF1 in LNCaP, but not in LN-56, and its suppression with Z-VAD-FMK indicates p53-dependent caspase activation in LNCaP in response to TNF-a. We made an attempt to de®ne which particular caspase(s) is involved in this process. There is an apparent discrepancy between our caspase-2 and -7 activation data: on the one hand are the results of DEVDase activity (Figure 2b ) and on the other hand are data pertaining to the inhibition of apoptosis by dierent caspase inhibitors (Table 1) . More speci®cally, we did not ®nd any dierences between LNCaP and LN-56 in DEVDase activity, but caspase-3 was not activated and caspase-7 was found to be dierentially activated. These data may be explained by the fact that many dierent caspases are capable of using DEVD as a substrate. Thus, the possibility remains that another caspase(s) is involved in TNF-a-mediated apoptosis. We also found that apoptosis was inhibited by the pan-caspase inhibitor Z-VAD-FMK, but other inhibitors of selected caspase subfamilies, including caspase-2 and -7 (Table 1) , were not able to inhibit apoptosis. Thus, some still unrecognized caspase(s) appear to play an essential role in p53-dependent TNF-a-induced apoptosis.
Our data also suggest that caspase(s) activation could be a factor leading to p53 accumulation. We found that the pan-caspase inhibitor Z-VAD-FMK decreased p53 accumulation after treatment of LNCaP with TNF-a. Thus, on the one hand, apoptosis in LNCaP is clearly p53-dependent. On the other hand, the accumulation of p53 itself is dependent on caspase activation. Together, these data suggest that there is a regulatory loop between p53 and the caspase(s) that ampli®es apoptotic responses in LNCaP. Inactivation of p53 in LN-56 may disrupt this regulatory loop which results in attenuation of caspase activation in LN-56. This, in turn could aid tumor growth in vivo. We observed that LN-56 is tumorigenic in nude mice whereas LNCaP is not. Interestingly, Srikanth and Kraft (1998) transfected LNCaP with the caspase inhibitor, cytokine response modi®er A (CrmA), and found that when LNCaP-CrmA cells were implanted in nude mice the tumors grew six times faster than parental LNCaP.
In summary, our data using the prostate carcinoma cell line LNCaP, and the subline we have generated, indicate that p53 plays an important, but as yet uncharacterized role, in TNF-a-mediated apoptosis. p53 involvement appears to occur both in the proximal portion of the signaling pathway as well as the more distal portion. Studies are ongoing to elucidate the mechanism of p53 action in these pathways. In addition, it will be important to determine if the results we have described here are applicable to other cell systems, including both solid tumors and hematopoietic cells.
Materials and methods
Cell culture
LNCaP and LN-56 cell lines were cultured in RPMI 1640 supplemented with 100 u/ml penicillin, 100 mg/ml streptomycin, 10 mM HEPES, 1 mM sodium pyruvate, 10% heatinactivated FCS, 0.1 mM 2-mercaptoethanol, and 2 mM Lglutamine. Cells were subcultured at 1 : 5 dilution by trypsinization (0.05% trypsin/1 mM EDTA) for 1 ± 2 min at room temperature. LNCaP mock transfectants and LN-56 were cultured for 2 ± 3 passages every 2 months in the presence of G-418 (400 mg/ml).
Generation of LNCaP transfectants with GSE-56
Retroviral vectors expressing GSE-56 were previously described (Ossovskaya et al., 1996; Nikiforov et al., 1997) . GSE-56 encodes a C-terminal portion of p53 and acts as an ecient inhibitor of p53 function by binding to oligomerization domain of p53. GSE-56 was cloned into LXSN retroviral vector (Miller and Rosman, 1989) under control of the LTR promoter. pLXSN also expresses neo gene, conferring resistance to G418, driven by the internal SV40 promoter. To generate LN-56 subline, LNCaP was transfected with the linearized plasmid and selected in the presence of G418 (400 mg/ml) as a bulk culture. Control LNCaP was transfected with the same plasmid without GSE-56. Expression of GSE-56 was con®rmed by Western blot analysis with mAbs (see Results).
Assessment of apoptosis
Apoptosis was estimated by quantitative DNA fragmentation assay as described by Matzinger (1991) . Cells were incubated overnight at 2610 5 cells in T-25¯ask with 5 ml of RPMI 1640 supplemented with 10% FCS in the presence of 10 mCi of [ 3 H] thymidine, then washed two times, counted and cultured for various times in 96-well tissue culture¯at-bottom plates (5 ± 10 000 cells/well) in the presence of dierent concentrations of TNF-a (R & D Systems, Minneapolis, MN, USA). The incorporated radioactivity was measured by liquid scincillation counting. All samples were measured in sextuplicate in at least two independent experiments. DNA fragmentation (apoptosis) was calculated as follows:
Per cent fragmentation cXpXmX in untreated group À cXpXmX in treated group cXpXmX in untreated group Â 100
Apoptosis was also measured by staining with 4,6-diamidino-2-phenylindole (DAPI). Cells were ®xed in 4% paraformaldehyde and stained with 10 mg/ml DAPI. Morphology of nuclei investigated by¯uorescence microscopy and cells with chromatin condensation were scored as apoptotic. To investigate the role of dierent inhibitors in apoptosis, the DNA fragmentation assay was performed in the presence of six dierent cell-permeable inhibitors of caspases:
all from Calbiochem, San Diego, CA, USA), and Ac-Ile-Glu-Thr-Asp (IETD) -aldehyde (CHO) (BIOMOL, Plymouth Meeting, PA, USA). In addition, we used ®ve non-caspase protease inhibitors: Ntosyl-L-phenylalanine-CMK (TPCK), N-tosyl-L-lysyl-CMK (TLCK), 3,4-dichloroisocoumarin (DCI), L-trans-epoxysuccinyl-L-leucylamido (4-guanidino) butane (E-64), and pepstatin A (all from Sigma, St. Louis, MO, USA). Inhibitors and TNF-a were added at the time of plating, and apoptosis was measured by DNA fragmentation assay.
Assay of caspase activity
In order to measure caspase activity, cytosolic extracts were prepared as described (Faleiro et al., 1997) by repeating freezing and thawing of cells in KPM buer (50 mM PIPESNaOH, pH 7.0, 50 mM KCI, 10 mM EGTA, 1.92 mM MgCl 2 , 1 mM DTT, 10 mg/ml cytochalasin B, and 2 mg/ml pepstatin, leupeptin, and antipain). 25 ± 50 mg of protein lysate was incubated at room temperature for 30, 60 and 90 min in assay buer (50 mM PIPES-KOH, ph 7.0, 0.1 mM EDTA, and 10% glycerol) with 20 mM of¯uorescent substrate: tetrapeptide Ac-Asp-Glu-Val-Asp-AMC (DEVD-AMC) as CPP32-like caspases (caspase-3) substrate, and tetrapeptide Ac-Tyr-Val-Ala-Asp-AMC (YVAD-AMC) as ICE-like caspases (caspase-1) substrate (both from Calbiochem). Fluorescence at 360/460 nm was measured with FL500¯uoremeter (Bio-Tek Instruments, Inc). Measurements were calibrated against a standard curve of 7-amino-4-methylcoumarin (AMC) (Sigma) and data were expressed in nM of released AMC per mg of lysate proteins.
Induction caspase activity in cell-free system Cytoplasmic extracts were prepared using KPM buer as described by Fearnhead et al. (1997) , diluted to a protein concentration of 2.5 mg/ml with a buer containing an ATPregeneration system (10 mM HEPES, pH 7.0; 5 mM EGTA, 50 mM NaCl, 2 mM MgCl 2 , 1 mM DTT, 2 mM ATP, 10 mM phosphocreatine and 50 mg/ml creatine kinase) and activated by 5 mM of cytochrome c (Sigma) and 1 mM dATP (Promega) in a total volume of 15 ml. After incubation at 378C for 45 min, caspase activity was measured with¯uorescent substrates as described in previous section.
Detection of cytochrome c release, production of reactive oxygen species (ROS) and disruption of the mitochondrial transmembrane potential (DC m )
To detect cytochrome c release, mitochondria-free cytosol was prepared as described (Yang et al., 1997) . Brie¯y, cells were lysed in ice cold buer M [20 mM HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 250 mM sucrose, 0.1 mM PMSF, 2 mg/ml pepstatin, 2 mg/ml leupeptin and 2 mg/ml aprotinin] by homogenization in a small glass homogenizer with te¯on pestle (50 strokes on ice). The homogenates were spun at 16 000 6g for 20 min at 48C, and the supernatants used for anti-cytochrome c Western blot analysis. To measure production of peroxide radicals, we used 10 mM of 2'-7'-dichloro¯uorescein diacetate (DCF-DA). To investigate the disruption of DC m , we used 40 nM 3,3'-dihexyloxacarbocyanine iodide (DiOC 6 (3)). Nonylacridine orange (NAO) was used as a probe that speci®cally interacts with mitichondrial cardiolipin and measures mitochondrial mass independently from DC m status of mitochondria. All these reagents were from Molecular Probes (Eugene, OR, USA). Cells were treated for 1, 2, 4 and 8 h with TNF-a, then incubated for 30 min at 378C in complete media with¯uorochromes, washed two times with PBS and analysed in FACS Vantage cyto¯uorometer (Becton Dickinson).
Western blotting
Western blot detection of proteins was performed as previously described (Rokhlin et al., 1997a,b) . Brie¯y, protein concentrations of cytosolic proteins were measured with the Bio-Rad DC protein microassay, 15 ± 25 mg of proteins were separated on 4 ± 20% gradient SDS ± PAGE and blotted to nitrocellulose membrane (Novex, San Diego, CA, USA). Membranes were blocked with 5% nonfat dry milk in PBS containing 0.1% Tween 20 and then incubated with mouse mAbs to caspase-3, -7 and -8 (Fearnhead et al., 1998) . Mab against caspases-3 was from Transduction Lab. (San Diego, CA, USA), mAb against caspase-8 was from Upstate Biotechnology (Lake Placid, NY, USA), rabbit Ab against caspase-7 was kindly provided by Dr Yuri Lazebnik (Cold Spring Harbor Lab., NY, USA). Mabs against caspase-2, TNFRI and TNFRII were from R & D Systems (Minneapolis, MN, USA). The blots were counterstained with goat antimouse or antirabbit IgG conjugated with HRP (Pierce, Rockford, IL, USA). The immunoreactive bands were visualized by incubation of the membrane with enhanced chemiluminescence reagent (Pierce). In separate experiments, total cells were prepared using Laemmli's sample buer and blots were incubated with Mab to poly(ADP-ribose) polymerase (PARP) (PharMingen), retinoblastoma protein (Rb, Ab-5, Oncogene), p21/WAF1 and p53, both from Oncogene (Uniondale, NY, USA).
